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New therapies are needed to improve survival for patients with Ewing sarcoma. Over the past decade, camptothecin agents such
as topotecan and irinotecan have demonstrated activity against Ewing sarcoma, especially in combination with alkylating agents.
Previous studies have shown camptothecin-based combinations to be tolerable outpatient strategies that are attractive for salvage
therapy. This paper highlights important issues related to drug dosing, schedule of administration, pharmacokinetics, toxicity,
and activity of commonly used camptothecin-based regimens. Also discussed are strategies for incorporating these regimens into
therapy for newly diagnosed patients, including several potential possibilities for combination with targeted agents.
1.Introduction
Current treatments usinginterval compression ofmultiagent
chemotherapy combined with surgery and/or radiation can
now cure the majority of patients with localized Ewing
sarcoma [1].However,outcomesare muchworseforpatients
who develop disease recurrence after initial therapy, or who
havemetastases atdiagnosis. Forexample, fewer than 20%of
patients with relapsed Ewing sarcoma are likely to be long-
term survivors [2], and patients who present with metastatic
bone and/or bone marrow disease at initial diagnosis share
a similarly poor prognosis [3]. New therapeutic approaches
are clearly necessary to improve overall survival for these
patients.
Chemotherapy for Ewing sarcoma has historically con-
sisted of alkylating agents and anthracyclines. Two modiﬁca-
tions of this backbone have led to signiﬁcant improvements
in outcome and have helped to deﬁne the current standard
of care. First, the addition of cassettes of ifosfamide and
etoposide onto the 3-drug combination of vincristine, dox-
orubicin, and cyclophosphamide has improved survival for
patients with localized disease [4]. Building on these results,
Womer et al. have shown that compression of the interval
between treatment courses from 3 weeks to 2 weeks provides
additional improvement in 3-year event-free survival, which
is now up to 76% for nonmetastatic patients [1]. Since
further modiﬁcation of this 5-drug regimen seems unlikely
to produce additional beneﬁts[5], future regimens will likely
need to incorporate new drugs in order to continue progress
in the ﬁeld.
Camptothecin agents have been evaluated in Ewing
sarcoma patients for the last decade. This class of agents is
attractive because of commercial availability, modest single-
agent activity, and demonstrated tolerability and synergy
with alkylating agents. Camptothecins exert cytotoxicity
by stabilizing the covalent complex between DNA and
topoisomerase I, the enzyme which relieves torsional strain
of DNA. This stabilization process prevents religation of
DNA, and the ensuing collision of the stabilized complex
with the advancing replication fork results in double strand
breaks and cell death. Preclinical studies have suggested
that activity of camptothecins is greatest when given in
combination with alkylating agents [6]. Mechanistically,
DNA damage from alkylators may increase the importance
of topoisomerase I for cell repair, thus rendering tumor
cells more sensitive to topoisomerase I inhibition [7]. This
activity is also enhanced in preclinical experiments when
protracted, low-dose administration is used compared to2 Sarcoma
single large doses [8], which is consistent with the S-phase-
speciﬁc mechanism of action.
This paper summarizes past Ewing sarcoma clinical trials
of the two most commonly used camptothecins, topotecan,
and irinotecan. Emphasis is placed on diﬀerences in their
toxicityproﬁles,schedules,androutesofadministration, and
partnering alkylating agents. Finally, an outline is provided
regarding potential future directions in which these agents
may be further developed.
2.Topotecan
2.1. Dosing and Schedule of Administration. Topotecan was
the ﬁrst camptothecin to be tested in Phase II trials against
Ewing sarcoma. Various schedules of administration have
been evaluated, including continuous infusions lasting from
72 hours [9]t o2 1d a y s[ 10]. Although continuous exposure
is intuitively attractive for maximizing activity of S-phase-
speciﬁc drugs, this approach may actually downregulate free
topoisomerase I and lead to drug resistance [11]. Therefore,
repeated administration on a protracted schedule may be
more beneﬁcial [8]. The most commonly used strategy is to
administer 5-day courses of topotecan as a daily 30-minute
infusion [12]. Dosages studied have ranged from 0.75–
3mg/m 2/day, depending on whether topotecan is given as a
single agent or in combination with other chemotherapeu-
tics. As discussed below, the greatest activity for topotecan
against Ewing sarcoma has been in combination with
cyclophosphamide, in which both drugs are given daily for
ﬁve days (i.e., d × 5 schedule) [13, 14]. Courses generally
are repeated every 21 days, and timely administration is
facilitated by the concurrent use of ﬁlgrastim.
2.2. Pharmacokinetics. There is signiﬁcant interpatient vari-
ability in topotecan pharmacokinetics, with 10-fold diﬀer-
ences in systemic clearance of topotecan lactone, which is
the form of topotecan with greatest antitumor activity [15].
This has led investigators at St. Jude Children’s Research
Hospitaltoexploretargetingthetopotecandoseofindividual
patients to achieve a prespeciﬁed systemic exposure that
correlated with activity in mouse tumor models. In one
study, administration of a standard topotecan dose resulted
in achieving the desired systemic exposure in only 53%
of patients. However, when patients underwent real-time
pharmacokinetic testing with the ﬁrst dose and then had
subsequent doses modiﬁed based on these results, 72%
of patients ﬁnished the course within the targeted drug
exposure range [15]. This experience, coupled with data
from other clinical trials, allowed for the development of
a population pharmacokinetic model which used factors
such as body surface area, glomerular ﬁltration rate, and
age to help predict up to 76% of interpatient variability in
topotecan clearance [16]. However, to date, neither use of
this model nor complicated pharmacokinetic targeting has
beenemployedfor treatment ofEwing sarcoma patients, and
it remains unclear to what extent the variance in systemic
exposure aﬀects overall activity of camptothecin agents,
particularly when used in combination with other drugs.
2.3. Route of Administration. Intravenous administration is
the most common method of topotecan administration;
however,itisbothcostlyandinconvenient,particularlywhen
protracted schedules are used. These factors have led to the
study of oral topotecan administration. Daw et al. reported
that the oral bioavailability of the intravenous preparation
givenorally was 0.27and 0.36when administered in a gelatin
capsule [17]. At the maximum tolerated dose (MTD) of
1.8mg/m2 givendaily for ﬁve days for two consecutiveweeks
(i.e., d × 5 × 2), systemic exposures were similar to those
required to achieve responses in mouse models. Further
studies have tested oral topotecan in combination with daily
oral cyclophosphamide [18] ,a n dw i t hb o t hd r u g st o g e t h e r
with geﬁtinib in a strategy described in greater detail below
[19]. Capsule formulation of topotecan is now approved by
the FDA for treatment of relapsed lung cancer, based in
part on encouraging results from an adult Phase III trial
showing similar activity and tolerability when oral dosing
of 2.3mg/m2/day × 5 was compared to 1.5mg/m2/day × 5
given intravenously [20]. There have been no reported Phase
II trials of oral topotecan in Ewing sarcoma patients to
date.
2.4. Toxicities. The primary dose-limiting toxicity of topote-
can is myelosuppression. In single-agent trials, nonhemato-
logicgrade3-4toxicitiessuchasnausea ordehydrationoccur
in less than 10% of patients [9, 10]. Rare events such as fever
and mucositis have also been reported to occur with single-
agent topotecan. With more protracted schedules in which
drug is administered for 5 days for two consecutive weeks
(i.e., d × 5 × 2 schedule), diarrhea also may be a prominent
complication [17].
When topotecanisgivenin combinationwith cyclophos-
phamide at the recommended Phase II dose (topotecan
0.75mg/m2/day × 5; cyclophosphamide 250mg/m2/day ×
5), myelosuppression remains the predominant toxicity. In
the largest reported Phase II experience, 163 (53%) of
307 courses given to 83 evaluable pediatric patients with
recurrent solid tumors resulted in grade 3-4 neutropenia,
despite all patients receiving prophylactic ﬁlgrastim [13].
However, no infectious deaths were observed, and Grades
3-4 infections were reported in only 11% of courses.
Thrombocytopenia reaching Grades 3-4 was observed in
44% of all courses.
2.5. Activity against Ewing Sarcoma. Although a sustained
complete response was reported in one of 5 Ewing sarcoma
xenograft models treated with single-agent topotecan [21],
clinical trials of topotecan by itself for recurrent Ewing
sarcoma have been relatively disappointing. For example,
the response rates for relapsed/refractory Ewing sarcoma
patients treated on three Phase II studies using various doses
and schedules were 4%, 8%, and 10% [9, 10, 12]. However,
combinationwith cyclophosphamidemarkedly improvesthe
response rate in this patient population, with two Phase II
studies showing response rates of 33% and 35% [13, 14].
In addition, approximately one-third of patients also had
stable disease or minor/mixed responses. The success ofSarcoma 3
Table 1: Summary of selected studies using topotecan-based therapy for patients with relapsed/refractory Ewing sarcoma.
Author [Ref] N Topotecan dose and
schedule Other drugs Response Rate
(complete + partial) Comments
Hawkins et al.
[10] 20 0.3mg/m2/d for 21-day
continuous infusion — 10%
Blaney et al.
[9] 3 1–1.3mg/m2/d for 72-hour
continuous infusion —4 %
Bernstein et al.
[12] 36 2mg/m2/d × 5— 8 %
Given as upfront window for 6
weeks in newly diagnosed
metastatic patients
Bernstein et al.
[12] 37 0.75mg/m2/d × 5 CPM 250mg/m2/d × 5 57%∗
Given as upfront window for 6
weeks in newly diagnosed
metastatic patients
Saylors et al.
[13] 17 0.75mg/m2/d × 5 CPM 250mg/m2/d × 5 35% 50% of patients received at least
6 courses before progression
Hunold et al.
[14] 49 0.75mg/m2/d × 5 CPM 250mg/m2/d × 5 33% Additional 26% with stable
disease
∗In newly diagnosed patients with metastaticdisease;CPM, cyclophosphamide.
this combination has resulted in its frequent use for salvage
therapy for patients in ﬁrst relapse.
A pilot study exploring higher doses of these agents
was recently reported by Kushner et al., using cyclophos-
phamide 4200mg/m2 by 48-hour infusion together with
topotecan 6mg/m2 by 72-hour infusion [22]. As expected,
myelosuppression was more frequent and severe, although
retreatment waspossiblewithin28days.Thelimitednumber
of Ewing sarcoma patients studied precludes assessment of
whether higher doses improve activity for this tumor type.
In addition, because alkylating agents may have signiﬁcant
single agent activity [23], determination of the relative
contribution of topotecan for treating Ewing sarcoma is
diﬃcult. Details of key clinical trials using topotecan for
Ewing sarcoma are summarized in Table 1.
3.Irinotecan
3.1. Dosing and Schedule of Administration. As with topote-
can, scheduling of irinotecan administration for pediatric
solid tumors has tried to capitalize on the S-phase-speciﬁc
mechanism ofaction,withmore protractedscheduleshaving
greater preclinical activity [8]. Many early trials used the
d × 5 × 2 schedule modeled after a pediatric Phase I trial
of intravenous irinotecan reported by Furman et al., which
established the MTD of 20mg/m2/day [24]. However, when
compared directly with a d × 5 schedule using a dose of
50mg/m2/day × 5, there was no diﬀerence in response rates
or incidence of grade 3-4 toxicities in patients with recur-
rent rhabdomyosarcoma who were receiving intravenous
irinotecan together with vincristine as a 6-week upfront
window [25]. This is the only pediatric trial which compared
two schedules in a randomized fashion, and the results
are similar to comparisons of diﬀerent schedules in colon
cancer patients [26]. Although it is possible that the more
protracted d × 5 × 2 schedule may have greater beneﬁt with
diseases other than rhabdomyosarcoma, it is likely that these
results will be extrapolated to future Ewing sarcoma trials
using irinotecan, given the improved patient convenience
and decreased costs of shorter treatment schedules.
3.2. Pharmacokinetics. Similar to topotecan, there is up
to one log variability in drug exposures between patients
receiving irinotecan [24]. Irinotecan is functionally a pro-
drug, which is converted by endogenous carboxylesterases
to the active topoisomerase I poison SN-38. In adults
receiving large single doses of irinotecan every 1–3 weeks,
metabolism is signiﬁcantly aﬀected by polymorphisms in
UGT1A1, which controls inactivation of SN-38 through
the process of glucuronidation [27]. For the approximately
10% of patients who are homozygous for the UGT1A1∗28
genotype, the risk of toxicity is substantial, resulting in an
FDA recommendation for dose reduction in starting doses
for these patients [28]. Importantly, this polymorphism has
had less impact in pediatric patients receiving protracted
irinotecan, as increased toxicity has not been associated with
UGT1A1∗28 in over 180 patients in 4 clinical trials [29–32].
To date, no genetic factors have been identiﬁed to reliably
predict toxicity in children receiving protracted irinotecan.
3.3. Route of Administration. As with topotecan, there has
been interest in oral administration of irinotecan as a way
to improve convenience and reduce cost. Three studies of
oral irinotecan have been completed and have demonstrated
that administration of the intravenous preparation mixed in
cran-grape juice, despite its bitter taste, is indeed feasible
over multiple courses in pediatric patients [31–34]. Cost
savings have been estimated to be up to ﬁvefold when com-
pared to intravenous administration [34]. Most importantly,
mean SN-38 exposures for patients treated at the MTD of
60mg/m2/day on the d × 5 × 2 schedule are similar to those
from patients receiving intravenous irinotecan at the MTD
of 20mg/m2/day [24, 32, 33]. Analogously, exposures from4 Sarcoma
patients receiving oral irinotecan at 90mg/m2/day correlate
with those receiving intravenous irinotecan at 50mg/m2/day
[31]. These studies show that for patients for whom oral
administration is suitable, this strategy can greatly reduce
costs and improve convenience, particularly when partner
drugs such as temozolomide are also given orally.
3.4. Toxicities. The dose-limiting toxicity of irinotecan is
dependent on the schedule used. For shorter administration
schedules, such as the single doses given every 1–3 weeks in
most adult studies, myelosuppression is dose limiting [26].
In contrast, late-onset diarrhea and abdominal cramping are
dose limiting when irinotecan is given on the protracted
d × 5 × 2 schedule [24]. Forthe intermediate d × 5schedule,
both myelosuppression and diarrhea can be seen, although
both toxicities are generally modest and manageable [29].
This favorable toxicity proﬁle has allowed for combination
with agents like temozolomide, in which the toxicity is pri-
marily hematologic. In fact, the temozolomide + irinotecan
c o m b i n a t i o nc a ng e n e r a l l yb eg i v e ni nt h r e ew e e kc o u r s e s
without the routine use of ﬁlgrastim support [35, 36].
Although severe diarrhea from protracted irinotecan
occurs in ≤20% of patients, such morbidity can impact
compliance [37], even when the tumor is responding
to treatment [38]. Recent eﬀorts to reduce irinotecan-
associated diarrhea in pediatric patients have included the
use of activated charcoal to reduce intestinal absorption of
the active metabolite SN-38 [39], as well as prophylactic
cephalosporins [33, 40]. Antibiotics work by reducing the
intestinal colonization of Gram-negative aerobic bacteria,
which produce the glucuronidase enzyme that converts
inactivated SN-38-glucuronidebackto active SN-38,causing
direct injury to the colon. Cephalosporins such as ceﬁxime
have been helpful in allowing 50% higher doses of oral
irinotecan to be tolerable, resulting in improved systemic
exposures [33]. Cephalosporin prophylaxis has been used in
all three reported trials of oral irinotecan, and also has been
usedin patientswho have experiencedseveregastrointestinal
toxicity with previous courses of intravenous irinotecan
[41]. However, use of antibiotics is not required for all
patients receiving standard doses of intravenous irinotecan,
and prolonged cephalosporins may be deleterious if given
unnecessarily. When used, cephalosporins are started at least
two days prior to chemotherapy and continued for at least
three days after chemotherapy. Therefore, patients receiving
5-day courses of irinotecan can be treated with a 10-day
course of antibiotics [31], while patients receiving longer
schedules of irinotecan are often continued indeﬁnitely on
antibiotics [32].
Although most patients receiving irinotecan and temo-
zolomidedonothavesigniﬁcant cumulativetoxicity,a recent
trial using vincristine, oral irinotecan, and temozolomide
(VOIT regimen) showed a subset of patients who expe-
rienced fatigue, anorexia, and weight loss that resulted in
removal from study [31]. This ﬁnding has not been reported
in previous studies, but does underscore the point that this
regimen may not be well tolerated over multiple courses by
all patients.
3.5. Activity against Ewing Sarcoma. Although not formally
tested against Ewing sarcoma models, there have been
reports of complete sustained responses with single-agent
irinotecan in xenograft models of primitive neuroectoder-
mal tumor (PNET), which is clinically similar to Ewing
sarcoma [42]. Building on this preclinical data, Bisogno
et al. reported a response rate of 38% in 13 patients with
recurrent/refractory extraosseous PNET who were treated
with protracted intravenous irinotecan given on a d × 5 × 2
schedule [38]. However, no responses were seen in 16
patients with recurrent/refractory PNET/ES in a Children’s
Oncology Group Phase II trial using intravenous irinotecan
50mg/m2/day × 5[ 29].
It is likely that the greatest antitumor activity of
irinotecan will be in combination with other drugs, such
as the methylating agent temozolomide. Houghton and
colleagues have demonstrated a schedule-dependent synergy
between temozolomide and irinotecan, in which methyl
groups placed on DNA by temozolomide cause recruitment
of topoisomerase I, thus potentiating the cytotoxic eﬀects
of irinotecan given at least one hour later [6, 7, 43]. This
two-drug combination has now been studied in three trials,
with reported response rates of 29%, 64%, and 63% [35,
36, 44]. Collectively, the cumulative results show partial
or complete responses in 32 (55%) of 58 patients with
recurrent/refractory Ewing sarcoma who have received 5-
day courses of temozolomide combined with intravenous
irinotecan given on the d × 5 × 2 schedule. Based on this
data, temozolomide + irinotecan, like cyclophosphamide +
topotecan, has become a widely used regimen for patients
with relapsed or refractory Ewing sarcoma. Interestingly,
the mechanisms of resistance to these camptothecin agents
appeartobediﬀerent[45],andresponses havebeenreported
with one regimen even when disease progression has been
noted with the other [35].
Based on the established role of vincristine in treating
E w i n gs a r c o m a ,a sw e l la st h es y n e r g yo b s e r v e di nr h a b -
domyosarcoma patients who are treated with vincristine +
irinotecan [41], more recent trials have added vincristine
onto the backbone of temozolomide + irinotecan [31,
46]. Use of vincristine may be particularly attractive for
newly diagnosed patients, for whom use of a known active
agent like vincristine may help reduce the rate of early
disease progression when using an upfront-window design
[41]. This addition does not seem to signiﬁcantly change
the toxicity proﬁle, although comparison studies with and
without vincristine have not been performed. Details of key
clinical trials using irinotecan for relapsed/refractory Ewing
sarcoma are provided in Table 2.
4.Comparisonof Topotecan-Based versus
Irinotecan-Based Regimens
Because of the relatively small number of patients with
recurrent Ewing sarcoma,randomized trials directlycompar-
ing regimens have not been performed. Table 3 summarizes
available information for commonly used salvage thera-
pies, highlighting toxicities, drug administration factors,Sarcoma 5
Table 2: Summary of studies using irinotecan-based therapy for patients with relapsed/refractory Ewing sarcoma.
Author
[Ref] N IRN dose and schedule Route of IRN
administration TEM dose Other
drugs
Response rate
(complete + partial) Comments
Bisogno
et al. [38] 13 20mg/m2/d × 5 × 2 IV — — 38% Study limited to soft
tissue PNET patients
Cosetti
et al. [37] 32 0 m g / m 2/d × 5 × 2I V —— 0
Bomgaars
et al. [29] 16 50mg/m2/d × 5I V — — 0
Casey
et al. [36] 20 10mg/m2/d × 5 × 2 IV 100mg/m2/d × 5 — 63% Median TTP = 8.3
months
Wagner
et al. [35] 14 10–20mg/m2/d × 5 × 2 IV 100mg/m2/d × 5 — 29%
50% of patients




et al. [44] 25 10mg/m2/d × 5 × 2 IV 100mg/m2/d × 5 — 60% Median TTP = 5.5
months
Wagner
et al. [31] 5 35–90mg/m2/day PO 100–150mg/m2/d
× 5 VCR 40%∗






11 5 m g / m 2/d × 5 × 2 IV 100mg/m2/d × 5 VCR 100% (n = 1)
∗Two of ﬁve patients had initial responses, but came oﬀ study prior to repeat imaging VCR, vincristine; TEM, temozolomide; IRN, irinotecan; TTP, time to
progression.
Table 3: Comparisonof commonlyused regimens for recurrent Ewing sarcoma.
Cyclophosphamide +
topotecan Temozolomide+ irinotecan High-dose ifosfamide Ifosfamide + carboplatin +
etoposide
Number of patients 66 58 37 22
Author (Ref) Saylors et al. [13]
Hunold et al. [14]
Casey et al. [36]
Wagner et al. [35]
Anderson et al. [44]
Ferrari et al. [23] Van Winkle et al. [47]
Primary toxicity Myelosuppression Gastrointestinal Myelosuppression Myelosuppression
Alopecia Yes Uncommon Yes Yes
Myeloid growth factor Yes Rarely Yes Yes
IV access required Generally Optional if administered
orally Yes Yes
Home administration Uncommon Common No No
Response rates
(complete + partial) 33–35% 29–63% 34% 48%
and response rates. The prioritization of salvage regimens
depends on several factors, including individual patient
considerations. Temozolomide + irinotecan is generally less
myelosuppressive than cyclophosphamide + topotecan and
does not usually require myeloid growth factor support.
However, some patients may develop diarrhea, fatigue,
or weight loss that becomes problematic. Although both
regimens can potentially be given orally, there is a larger
published pediatric experience with oral irinotecan (sum-
marized in [34]). Home administration of chemotherapy,
whether intravenously or oral, is often attractive for patients,
and has been well described with temozolomide+ irinotecan
[35]. Home administration also helps reduce cost, which
can be considerable if multiple courses are administered.
At our institution, patient drug costs alone for an individual
with body surface area of 1.5m2 receiving a standard 5-
daycourseofcyclophosphamide+topotecan+ pegﬁlgrastim
are $21,966 (USD), compared to a standard 5-day course of
temozolomide + oral irinotecan costing $17,599. The total
number of courses given to patients with relapsed disease
is variable and depends on both response and tolerability.
Extended treatment using cyclophosphamide + topotecan
(up to 11 courses) and temozolomide + irinotecan (up to
20 courses) has been described, but the beneﬁts of such
protracted therapy are unclear. Relapsed patients may also
beneﬁt from local control measures such as radiotherapy
[48], which in most situations can be administered concur-
rently with either regimen.6 Sarcoma
5.FurtherDevelopmentofCamptothecinsin
Treatment of Ewing Sarcoma
There are two general ways that camptothecin regimens
can be incorporated into frontline therapies. The ﬁrst is to
build on standard 5-drug therapy by inserting cassettes of
either cyclophosphamide + topotecan, or temozolomide +
irinotecan + vincristine. Based on the success of admin-
istering standard 5-drug treatment in two-week intervals
[1], the Children’s Oncology Group (COG) has performed
a feasibility trial examining whether cyclophosphamide +
topotecan may also be given in intervals shorter than the
typical3 weeks. Published resultsfrom thistrial are currently
pending; however, the Children’s Oncology Group has now
opened a randomized Phase III trial in which patients
with newly diagnosed localized Ewing sarcoma may receive
cassettes of vincristine, cyclophosphamide, and topotecan in
2-weekintervalsinterspersed inthestandard 5-drugregimen
(http://clinicaltrials.gov/#NCT01231906).
The second strategy is to use camptothecin regimens as
a therapeutic backbone on which to add targeted therapies.
Several candidate agents have been evaluated either in
clinical trials or preclinical experiments and are discussed
below.
6.CombinationStrategies
6.1. Bevacizumab. Bevacizumab is a monoclonal antibody
directed against vascular endothelial growth factor, and
targets the newly developing blood vessels necessary for
sustaining solid tumors. Although originally thought to have
antitumor activity by “choking oﬀ” the blood supply to
tumors, the primary eﬀect of bevacizumab may actually be
related to normalization of the tumor-associated vasculature
by pruning oﬀ immature or poorly formed blood vessels,
thereby improving distribution of chemotherapy [49]. This
principle was demonstrated in preclinical experiments by
Dickson et al., in which intratumoral topotecan concentra-
tions improved following pretreatment with bevacizumab,
which corresponded to better antitumor activity [50]. Given
the long half-life of bevacizumab, and the demonstration
thatintratumoralperfusion peaks2daysafteradministration
and returns to baseline within 7 days, combination with
protracted courses of camptothecins seems reasonable. The
COG has recently ﬁnished a pilot study in which bevac-
izumab was added to the backbone of vincristine, cyclo-
phosphamide, and topotecan for patients with relapsed/
refractory Ewing sarcoma [51]. This combination was fea-
sible, and future studies are ongoing, such as an institu-
tional trial at Cincinnati Children’s Hospital which com-
bines bevacizumab with the VOIT regimen (vincristine,
oral irinotecan, and temozolomide) (http://clinicaltrials
.gov/#NCT00786669).
6.2. IGF-1R Antibodies. Signaling through the insulin-like
growth factor type I receptor (IGF-1R) is critical for the
growthandmaintenanceofEwingsarcomacells,anditsinhi-
bition oﬀers an attractive new target for therapy (reviewed
in [52]). IGF-1R also has important eﬀects on apoptosis
and response to DNA damage. Wang et al. have shown
that the concomitant use of an IGF-1R antibody together
with irinotecan produced additive eﬀects and resulted in
a 93% reduction in tumor volume in a mouse model
of thyroid carcinoma [53]. Clinical trials of anti-IGF-1R
antibodies have already demonstrated single-agent activity
against relapsed Ewing sarcoma [54], with one of the largest
showing 2 (13%) of 16 patients having objective responses,
with another 8 (50%) having stable disease for at least 4
months [55]. The COG is now using the IMC-A12 an-
tibody together with multiagent chemotherapy in a study
for metastatic rhabdomyosarcoma (http://clinicaltrials.gov/
#NCT01055314), and combination strategies for Ewing
sarcoma are in early development (http://clinicaltrials.gov/
#NCT01182883).
6.3. Geﬁtinib. Geﬁtinib is a small molecule inhibitor of
the epidermal growth factor receptor and is used clinically
for treatment of lung cancer. Geﬁtinib competes with
camptothecins at the level of the ABCG2 drug eﬄux pump,
causing inhibition of the pump without directly serving as
as u b s t r a t e[ 56]. This allows geﬁtinib to reverse irinotecan
resistance in vitro [57], even in cell lines that lack expression
of the epidermal growth factor receptor. Since ABCG2
is expressed in normal small intestine, administration of
geﬁtinib also improves by threefold the oral bioavailability
of irinotecan in mice [56]. This data has led to recent
trials of geﬁtinib + oral irinotecan for refractory pediatric
solid tumors [58], as well as geﬁtinib + oral topotecan and
cyclophosphamide in children with relapsed neuroblastoma
[19].
6.4. mTOR Inhibitors. Like geﬁtinib, the mTOR inhibitor
rapamycin inhibits ABCG2 without being a substrate of
this pump. Accordingly, rapamycin has eﬀectively reversed
in vitro resistance to topotecan [59]. Rapamycin is also
synergistic with irinotecan in mouse models of colon cancer,
perhaps through inhibition of hypoxia-inducible factor-1
alpha [60]. mTOR inhibitors have had some modest single-
agent eﬀects against Ewing sarcoma xenografts [61], and
a recently opened COG Phase I trial will examine the
combination of temozolomide and irinotecan together with
the once-weekly mTOR inhibitor temsirolimus (http://clin-
icaltrials.gov/#NCT01141244).
6.5. PARP Inhibitors. Poly (ADP-ribose) polymerase (PARP)
is a key mediator of DNA base excision repair and recovery
fromDNAstrandbreaksandprotectcellsfromthetoxicityof
various chemotherapy agents. Inhibitors of PARP can eﬀec-
tively enhance the in vitro and in vivo activity of topotecan,
irinotecan, and temozolomide against colorectal and lung
cancer cell lines and xenograft models [62]. Interestingly,
Tentori et al. demonstrated that PARP inhibition not only
increased the activity of temozolomide + irinotecan against
tumor xenografts, but also reduced intestinal injury and
diarrhea in mouse models, thus oﬀering the possibility of
improved activity with less toxicity [63].Sarcoma 7
6.6. New Camptothecins in Development. EZN-2208 is
a novel polymer-drug conjugate which links the active
metabolite of irinotecan (SN-38) with a multiarm polyethy-
lene glycol. This allows for intravenous administration once
every three weeks, with sustained SN-38 exposures that are
superior to those seen with protracted irinotecan [64]. In
experimental models, activity has been seen even in tumors
resistant to irinotecan [65]. Pediatric trials of EZN-2208 are
set to begin soon.
7.Conclusions
Considerable progress has been made in evaluating camp-
tothecin agents for treatment of Ewing sarcoma, and both
topotecan and irinotecan clearly are active when combined
with alkylating agents. These drugs have several similari-
ties, including superior activity when given on protracted
schedules, wide interpatient variability in pharmacokinetics,
and the potential for oral administration. Both cyclophos-
phamide + topotecan and temozolomide + irinotecan are
nowwidely usedforpatientswithrecurrent tumorsand oﬀer
a good chance of response or disease stabilization. Decisions
regarding which regimen to use are often based on toxicity
and drug administration issues. The activity and tolerability
seen with both regimens assures further exploration in
upcoming trials, either as cassettes which are incorporated
intostandardﬁve-drugregimensorastherapeuticbackbones
on which to add targeted agents.
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